AMNOG

Policies on Medical Research in Germany: Boehringer Ingelheim’s Perspective

Zahra Ahangar Atashi - 5 August 2024

Policies recently adopted by the German government have received mixed reviews from Boehringer Ingelheim, the country’s largest pharmaceutical company. Dr. Fridtjof Traulsen, CEO of...

AMNOG

Innovations in Advanced Therapy Medicinal Products (ATMPs): A New Horizon in Medical Treatment

Kardelen Alsan - 3 April 2024

Advanced Therapy Medicinal Products (ATMPs) stand out as beacons of hope and innovation in the rapidly evolving landscape of medical research and treatment. The...

Schönermark Kielhorn Collegen

Advancements and Insights in Germany’s Orphan Drug Sector: A Comprehensive Review of Early 2024

Kardelen Alsan - 3 April 2024

The AMNOG Orphan Tracker report for the first two months of 2024 provides an insightful look into the state of orphan drug procedures in...